The administration of entacapone prevents l-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates

Experimental Neurology

Volumn 208, Issue 2, 2007, Pages 177-184

  Zubair, Mohammed ^a   Jackson, Michael J ^a   Tayarani Binazir, Kayhan ^a   Stockwell, Kim A ^a   Smith, Lance A ^a   Rose, Sarah ^a   Olanow, Warren ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Continuous dopaminergic stimulation; Dyskinesia; Entacapone; l dopa; MPTP; Primates; Ropinirole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; ROPINIROLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; TREATMENT DURATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; CATECHOLS; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DYSKINESIA, DRUG-INDUCED; FEMALE; INDOLES; LEVODOPA; MALE; MOTOR ACTIVITY; NITRILES;

EID: 36148968428     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.05.002     Document Type: Article

References (34)

1. Bedard P.J., Di Paolo T., Falardeau P., et al. Chronic treatment with l-dopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 379 2 (1986) 294-299
2. Block G., Liss C., Reines S., et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur. Neurol. 37 1 (1997) 23-27
3. Burns R.S., Chiueh C.C., Markey S.P., et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 80 14 (1983) 4546-4550
4. Chase T.N., Baronti F., Fabbrini G., et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39 11 Suppl. 2 (1989) 7-10 (discussion 19)
5. Chase T.N., Konitsiotis S., and Oh J.D. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv. Neurol. 86 (2001) 355-360
6. Dupont E., Andersen A., Boas J., et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol. Scand. 93 1 (1996) 14-20
7. Engber T.M., Susel Z., Juncos J.L., et al. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur. J. Pharmacol. 168 3 (1989) 291-298
8. Fahn S. Adverse effects of levodopa. In: Olanow C.W., and Lieberman A. (Eds). The Scientific Basis for the Treatment of Parkinson's Disease (1992), Parthenon Publishing Group, Lancs 89-112
9. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. 47 4 Suppl. 1 (2000) S90-S99 (discussion S99-104)
10. Jenner P. Experimental models of Parkinson's disease. In: Ronken E., and van Scharrenburg G. (Eds). Parkinson's Disease (2002), IOS Press, London 39-50
11. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62 1 Suppl. 1 (2004) S47-S55
12. Juncos J.L., Engber T.M., Raisman R., et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann. Neurol. 25 5 (1989) 473-478
13. Koller W.C. Treatment of early Parkinson's disease. Neurology 58 4 Suppl. 1 (2002) S79-S86
14. Koller W.C., Hutton J.T., Tolosa E., et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53 5 (1999) 1012-1019
15. Kurth M.C., Tetrud J.W., Tanner C.M., et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 43 9 (1993) 1698-1703
16. Maratos E.C., Jackson M.J., Pearce R.K., et al. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than l-dopa in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp. Neurol. 179 1 (2003) 90-102
17. Marsden C.D., and Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1 7954 (1976) 292-296
18. Nilsson D., Nyholm D., and Aquilonius S.M. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol. Scand. 104 6 (2001) 343-348
19. Nutt J.G., Carter J.H., Lea E.S., et al. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov. Disord. 12 3 (1997) 285-292
20. Obeso J.A., Grandas F., Herrero M.T., et al. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur. J. Neurosci. 6 6 (1994) 889-897
21. Obeso J., Linazasoro G., Gorospe A., et al. Complications associated with chronic levodopa therapy in Parkinson's disease. In: Olanow C.W., and Obeso J. (Eds). Beyond the Decade of the Brain vol. 2 (1997), Wells Medical, Royal Tunbridge Wells 11-35
22. Olanow C.W. The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 58 4 Suppl. 1 (2002) S33-S41
23. Olanow C.W., and Obeso J.A. Preventing levodopa-induced dyskinesias. Ann. Neurol. 47 4 Suppl. 1 (2000) S167-S176 (discussion S176-168)
24. Olanow W., Schapira A.H., and Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23 Suppl. 10 (2000) S117-S126
25. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5 8 (2006) 677-687
26. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284 15 (2000) 1931-1938
27. Pearce R.K., Banerji T., Jenner P., et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset. Mov. Disord. 13 2 (1998) 234-241
28. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342 20 (2000) 1484-1491
29. Ruottinen H.M., and Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 19 4 (1996) 283-296
30. Russ H., Mihatsch W., Gerlach M., et al. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?. Neurosci. Lett. 123 1 (1991) 115-118
31. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123 Pt 11 (2000) 2297-2305
32. Smith L.A., Jackson M.J., Al-Barghouthy G., et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. 20 3 (2005) 306-314
33. Stacy M., Bowron A., Guttman M., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov. Disord. 20 6 (2005) 726-733
34. Syed N., Murphy J., Zimmerman Jr. T., et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov. Disord. 13 2 (1998) 336-338